Evidence Level
Psyllium husk is a well-researched fiber supplement with robust evidence supporting its health benefits. A 2009 meta-analysis by Wei et al. (2009) of 21 randomized placebo-controlled trials involving 1,717 participants demonstrated that psyllium significantly lowers total and LDL cholesterol in a dose- and time-dependent manner. This finding underpins the FDA's approved health claim for psyllium in reducing the risk of coronary heart disease.
In the context of diabetes management, Gibb et al. (2015) conducted a meta-analysis of 35 randomized controlled trials with over 1,000 participants, showing that psyllium improves glycemic control by lowering fasting blood glucose (-37 mg/dL) and HbA1c levels (-0.97%) in type 2 diabetes patients. These findings highlight the role of psyllium in managing blood sugar levels.
Additionally, recent studies have explored the gut microbiota effects of psyllium. Jalanka et al. (2019) investigated the impact of psyllium husk on intestinal microbiota in constipated patients and healthy controls, providing insights into its potential mechanisms of action. Furthermore, Holte et al. (2025) reported that psyllium husk reduced Low Anterior Resection Syndrome (LARS) scores by 7.7 points and improved quality of life in rectal cancer patients with LARS.
Overall, psyllium husk is supported by strong evidence for its benefits in lipid management, glycemic control, and gut health, making it a valuable supplement in various clinical contexts.